Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19208198 | 0.82 | SMN1; SMN2 (0.57) | NPC1LMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL31715213 | 0.81 | NPC1 (0.64) | NPC1LMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL19208815 | 0.81 | NPC1 (0.57) | NPC1LMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL7008027 | 0.81 | NPC1 (0.60) | NPC1LMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL173434 | 0.80 | NPC1 (0.68) | NPC1LMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL4242279 | 0.79 | NPC1 (0.61) | NPC1LMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL4581244 | 0.78 | FNTA (0.46) | ALDH1A1RAB9ASMN1; SMN2KDM4ETSHR | |
| SCHEMBL24452557 | 0.77 | NPC1 (0.65) | NPC1LMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1406981 | 0.77 | NPC1 (0.58) | NPC1LMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1407148 | 0.76 | NPC1 (0.61) | NPC1LMNAALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559515-B2 | Indole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559515-B2 | Indole compounds and analogues thereof | C5, IDO1, IDO2 | NPC1 279/4885LMNA 2366/4885ALDH1A1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.